588 564

Cited 0 times in

신경병증통증에 대한 Gabapentin의 유효성과 안전성

Other Titles
 Safety and Efficacy of Gabapentin in Neuropathic Pain 
Authors
 윤덕미 
Citation
 Korean Journal of Pain (대한통증학회지), Vol.17(1) : 34-41, 2004 
Journal Title
Korean Journal of Pain (대한통증학회지)
ISSN
 2005-9159 
Issue Date
2004
Keywords
gabapentin ; neuropathic pain
Abstract
Background: The newer generation of anticonvulsant, gabapentin is probably the most useful agent for neuropathic pain. This report reviews prospective safety and efficacy data collected in actual clinical situations for various neuropathic pains. Methods: This was an open label, prospective, non-comparative, clinical study of gabapentin for the treatment of various neuropathic pain syndromes. 392 patients were enrolled between June, 2002 and August, 2003, and 42 pain specialists from 40 private pain clinics were participated in the study. Safety and efficacy were assessed in 177 patients after a minimum of 6 weeks of gabapentin treatment, with starting and final doses determined by the prescribing physician. The primary efficacy measure was a change in the average daily pain score (DPS) based on an 11-point Likert scale (0, no pain; 10, worst possible pain) and change in sleep interference (SI) from baseline to the final week of therapy. Results: In 157 (88.7%) of the 177 patient gabapentin was assessed as effective, as follows; 72 patients (40.7%) were markedly improved; 85 patients (48.0%) moderately improved; 16 patients (9.0%) slightly improved; and 4 patients were unchanged. Patients that rated baseline pain as severe improved in 86.2 % (50/58 patients) of cases and 90% of patients that rated their baseline pain as mild to moderate showed improvement. Various neuropathic pains except other polyneuropathies, were clinically improved by more than 80%. Most patients were started at 300 mg/day of gabapentin, and were maintained within 600 900 mg/day at the end of the study. There was a significant reduction in the average daily pain score from 7.3 to 2.8 (P < 0.0001). Sleep Interference was also significantly improved from 5.0 to 1.6 points after gabapentin administration (P <0.0001). Of the 392 patients, 58 patients (14.8%) experienced 67 adverse events (17.1%). Most events were mild but 6.0% were severe. Conclusions: Gabapentin is effective and safe drug for the treatment of neuropathic pain.
Files in This Item:
T200400338.pdf Download
DOI
10.3344/jkps.2004.17.1.34
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Anesthesiology and Pain Medicine (마취통증의학교실) > 1. Journal Papers
Yonsei Authors
Yoon, Duck Mi(윤덕미)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/112085
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links